2019 related articles for article (PubMed ID: 26387758)
21. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.
Rizos D; Eleftheriades M; Karampas G; Rizou M; Haliassos A; Hassiakos D; Vitoratos N
Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):225-30. PubMed ID: 24035323
[TBL] [Abstract][Full Text] [Related]
22. Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation.
Lai J; Garcia-Tizon Larroca S; Peeva G; Poon LC; Wright D; Nicolaides KH
Fetal Diagn Ther; 2014; 35(4):240-8. PubMed ID: 24853452
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal changes in maternal hemodynamics in a population at risk for pre-eclampsia.
Khalil A; Garcia-Mandujano R; Maiz N; Elkhouli M; Nicolaides KH
Ultrasound Obstet Gynecol; 2014 Aug; 44(2):197-204. PubMed ID: 24652784
[TBL] [Abstract][Full Text] [Related]
24. Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsia.
Turpin CA; Sakyi SA; Owiredu WK; Ephraim RK; Anto EO
BMC Pregnancy Childbirth; 2015 Aug; 15():189. PubMed ID: 26303772
[TBL] [Abstract][Full Text] [Related]
25. Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30-34 weeks.
Bakalis S; Peeva G; Gonzalez R; Poon LC; Nicolaides KH
Ultrasound Obstet Gynecol; 2015 Oct; 46(4):446-51. PubMed ID: 25826154
[TBL] [Abstract][Full Text] [Related]
26. Soluble Fms-like tyrosine kinase-1 to placental growth factor ratio in mid-pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women.
Forest JC; Thériault S; Massé J; Bujold E; Giguère Y
Clin Chem Lab Med; 2014 Aug; 52(8):1169-78. PubMed ID: 24535301
[TBL] [Abstract][Full Text] [Related]
27. Prediction of pre-eclampsia during early pregnancy in primiparas with soluble fms-like tyrosine kinase-1 and placental growth factor.
Rohra DK; Zeb A; Qureishi RN; Azam SI; Khan NB; Zuberi HS; Sikandar R
Natl Med J India; 2012; 25(2):68-73. PubMed ID: 22686711
[TBL] [Abstract][Full Text] [Related]
28. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.
Leaños-Miranda A; Campos-Galicia I; Isordia-Salas I; Rivera-Leaños R; Romero-Arauz JF; Ayala-Méndez JA; Ulloa-Aguirre A
J Hypertens; 2012 Nov; 30(11):2173-81. PubMed ID: 22902831
[TBL] [Abstract][Full Text] [Related]
29. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
Gallo DM; Wright D; Casanova C; Campanero M; Nicolaides KH
Am J Obstet Gynecol; 2016 May; 214(5):619.e1-619.e17. PubMed ID: 26627730
[TBL] [Abstract][Full Text] [Related]
30. The soluble fms-like tyrosin kinase-1 (sFLT-1) to placental growth factor (PIGF) ratio as a possible indicator for the severity of preeclampsia - single institution experience.
Müller A; Horvat V; Vulin M; Mandić S; Šerić V; Vidosavljević D
Med Glas (Zenica); 2019 Feb; 16(1):53-59. PubMed ID: 30680983
[TBL] [Abstract][Full Text] [Related]
31. Association between angiogenic factors and signs of arterial aging in women with pre-eclampsia.
Akhter T; Wikström AK; Larsson M; Larsson A; Wikström G; Naessen T
Ultrasound Obstet Gynecol; 2017 Jul; 50(1):93-99. PubMed ID: 27256927
[TBL] [Abstract][Full Text] [Related]
32. Angiogenic profile in the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort.
Jääskeläinen T; Heinonen S; Hämäläinen E; Pulkki K; Romppanen J; Laivuori H;
Pregnancy Hypertens; 2018 Oct; 14():252-259. PubMed ID: 29803331
[TBL] [Abstract][Full Text] [Related]
33. Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Da Silva AB; Nicolaides KH
Ultrasound Obstet Gynecol; 2020 Sep; 56(3):400-407. PubMed ID: 32441401
[TBL] [Abstract][Full Text] [Related]
34. Prediction of hypertensive disorders after screening at 36 weeks' gestation: comparison of angiogenic markers with competing-risks model.
Schiattarella A; Magee LA; Wright A; Syngelaki A; Akolekar R; Von Dadelszen P; Nicolaides KH
Ultrasound Obstet Gynecol; 2023 Sep; 62(3):345-352. PubMed ID: 37329494
[TBL] [Abstract][Full Text] [Related]
35. Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks.
Fadigas C; Peeva G; Mendez O; Poon LC; Nicolaides KH
Ultrasound Obstet Gynecol; 2015 Aug; 46(2):191-7. PubMed ID: 25825848
[TBL] [Abstract][Full Text] [Related]
36. Ophthalmic artery Doppler and biomarkers of impaired placentation at 36 weeks' gestation in pregnancies with small fetuses.
Arechvo A; Wright A; Nobile Recalde A; Liandro R; Charakida M; Nicolaides KH
Ultrasound Obstet Gynecol; 2024 Mar; 63(3):358-364. PubMed ID: 37902727
[TBL] [Abstract][Full Text] [Related]
37. The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio.
Buhimschi CS; Baumbusch MA; Dulay AT; Lee S; Wehrum M; Zhao G; Bahtiyar MO; Pettker CM; Ali UA; Funai EF; Buhimschi IA
BJOG; 2010 Feb; 117(3):321-30. PubMed ID: 19943826
[TBL] [Abstract][Full Text] [Related]
38. The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies.
Saleh L; Tahitu SIM; Danser AHJ; van den Meiracker AH; Visser W
Pregnancy Hypertens; 2018 Oct; 14():222-227. PubMed ID: 29678353
[TBL] [Abstract][Full Text] [Related]
39. Threshold of soluble fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia.
Ohkuchi A; Hirashima C; Matsubara S; Takahashi K; Matsuda Y; Suzuki M
Hypertension; 2011 Nov; 58(5):859-66. PubMed ID: 21947468
[TBL] [Abstract][Full Text] [Related]
40. Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks' gestation.
Dragan I; Georgiou T; Prodan N; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2017 Jan; 49(1):73-77. PubMed ID: 27619203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
